Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-59804
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50303
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in CALGB 51101 (Alliance) Batchelor, T , Giri, S , Stark, A , Bartlett, N , Hsi, E , Cheson, B ... - ASCO - J Clin Oncol. - 2020 Abstract - Primary - Primary - Lymphoma - CALGB-51101
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary - Primary - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary - Primary - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50904
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-50206
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer - 2006 Manuscript - Primary - Long-Term-Followup - Lymphoma - CALGB-9153
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann. Oncol. - 2012 Manuscript - Primary - Primary - Lymphoma - CALGB-50402
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50402
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary - Primary - Lymphoma - CALGB-50402
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Czuczman, Myron S , Porcu, Pierluigi , Johnson, Jeffrey ... - - Leuk. Lymphoma - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-59901
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 Damon, Lloyd E. , Johnson, Jeffrey L. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009 Manuscript - Primary - Primary - Lymphoma - CALGB-59909
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary - Primary - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013 Abstract - Secondary - Primary - Lymphoma - CALGB-50403
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 Furman, Richard R. , Grossbard, Michael L. , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2011 Manuscript - Primary - Primary - Lymphoma - CALGB-9254
Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20) Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50701
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Grant, Barbara W , Jung, Sin-Ho , Johnson, Jeffrey L ... - - Cancer - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50701
Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008 Abstract - Secondary - Primary - Correl Sci NOS - CALGB-50103
Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study Hsi, E. , Jung, S. , Lai, R. , Johnson, J. , Cook, J. , Jones, D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Hsi, Eric D. , Jung, Sin-Ho , Lai, Raymond , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909
Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance). Kaplan, L. D. , Jung, S. H. , Bartlett, N. C. , Johnson, J. , Byrd, J. ... - ASH - Hematol Oncol - 2013 Abstract - Primary - Preliminary - Lymphoma - CALGB-50403
A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403 Kaplan, L. D. , Jung, S. , Johnson, J. L. , Linker, C. , Byrd, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Lymphoma - CALGB-50403
Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403 Kaplan, Lawrence D. , Maurer, Matthew J. , Stock, Wendy ... - - Am. J. Hematol. - 2020 Manuscript - Primary - Primary - Lymphoma - CALGB-50403
Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance) Kaplan, Lawrence D. , Maurer, Matthew , Stock, Wendy , Fulton, Noreen ... - ASH - Blood - 2018 Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50403
Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403 Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - CALGB-50403
Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone? Kostakoglu, L. , Schoder, H. , Hall, N. C. , Straus, D. J. ... - ASH - ASH Annual Meeting Abstracts - 2011 Abstract - Secondary - Primary - Lymphoma - CALGB-50203
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results Kostakoglu, L. , Straus, D. J. , Schoder, H. , Lacasce, A. S. ... - ASH - ASH Annual Meeting Abstracts - 2008 Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-50203
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Kostakoglu, Lale , Schöder, Heiko , Johnson, Jeffrey L ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary - Primary - Lymphoma - CALGB-50203
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804
Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803 Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin-Ho ... - ASH - Blood - 2016 Abstract - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin‐Ho ... - - Cancer Med - 2018 Manuscript - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803
CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Leonard, J. , Jung, S.-H. , Johnson, J. L. , Bartlett, N. L. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Lymphoma - CALGB-50401
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) Leonard, John P. , Jung, Sin-Ho , Johnson, Jeffrey ... - - J. Clin. Oncol - 2015 Manuscript - Primary - Primary - Lymphoma - CALGB-50401
Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab and GS-1101 (Idelalisib) in recurrent follicular lymphoma Leonard, John P. , Jung, Sin-ho ... - ICML - Hematol Oncol - 2013 Abstract - No-Endpoint - Trial-Description-Only - Lymphoma - A051202
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Liu, Hongtao , Johnson, Jeffrey L. , Koval, Greg , Malnassy, Greg ... - - Haematologica - 2012 Manuscript - Secondary - Primary - Lymphoma - CALGB-59909
Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance) Malnassy, Greg , Geyer, Susan , Fulton, Noreen , Koval, Greg ... - - Blood - 2013 Abstract - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - CALGB-10403 , CALGB-59909
CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, P. , Jung, S.-H. , Johnson, J. , Elstrom, R. , Bartlett, N. L. ... - ICML - Hematol Oncol - 2013 Abstract - Primary - Preliminary - Lymphoma - CALGB-50803
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) Martin, P , Jung, S -H , Pitcher, B , Bartlett, N L , Blum, K A ... - - Ann. Oncol - 2017 Manuscript - Primary - Primary - Lymphoma - CALGB-50803
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Lymphoma - CALGB-50803
Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, Peter , Jung, Sin-Ho , Pitcher, Brandy , Bartlett, Nancy ... - ICML - Hemato Oncol - 2017 Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50803
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. Morrison, V. A. , Johnson, J. L. , Jung, S. , Leonard, J. P. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Lymphoma - CALGB-50501
Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501) Morrison, V. A. , Jung, S.-H. , Johnson, J. , Lacasce, A. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary - Preliminary - Lymphoma - CALGB-50501
Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501 Morrison, V. A. , Jung, S. , Johnson, J. , Leonard, J. ... - - Ann. Oncol. - 2011 Abstract - Primary - Preliminary - Lymphoma - CALGB-50101
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501) Morrison, V. A. , Jung, S. , Leonard, J. ... - - J. Clin. Oncol. - 2011 Abstract - Primary - Preliminary - Lymphoma - CALGB-50501
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501) Morrison, Vicki A. , Jung, Sin-Ho , Johnson, Jeffrey , LaCasce, Ann ... - - Leuk. Lymphoma - 2015 Manuscript - Primary - Primary - Lymphoma - CALGB-50501
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - - Blood - 2010 Abstract - Primary - Primary - Leukemia - CALGB-10002
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002 Rizzieri, David A. , Johnson, Jeffrey L. , Byrd, John C. ... - - Br. J. Haematol. - 2014 Manuscript - Primary - Primary - Leukemia - CALGB-10002
Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance) Rosenbaum, Cara A. , Pitcher, Brandelyn , Bartlett, Nancy L ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - CALGB-50901
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Rosenbaum, Cara A , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Br. J. Haematol. - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50901
BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance) Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Secondary - Primary - Lymphoma - CALGB-50202
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202) Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50202
Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202 Rubenstein, J. L. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50202
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020 Manuscript - Secondary - Primary - Lymphoma - CALGB-50303
Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602 Smith, S. M. , Bartlett, N. L. , Johnson, J. L. , Jung, S. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Lymphoma - CALGB-50602
Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: Final Analysis of CALGB 8691 Smith, SM , Johnson, J , Cheson, BD , Canellos, G , Petroni, G ... - - Leuk. Lymphoma - 2009 Manuscript - Primary - Primary - Lymphoma - CALGB-8691
Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202 Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014 Abstract - Secondary - Meta-Analysis - Lymphoma - A051201 , A051202
Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - - Lancet Haematol - 2017 Manuscript - Primary - Primary - Lymphoma - A051201 , A051202
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) Smith, Sonali M. , Schöder, Heiko , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2013 Manuscript - Primary - Primary - Lymphoma - CALGB-50602
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Smith, Sonali M , Grinblatt, David , Johnson, Jeffrey L ... - - Br. J. Haematol. - 2008 Manuscript - Primary - Primary - Lymphoma - CALGB-50002
Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401) Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015 Abstract - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Sohani, Aliyah R , Maurer, Matthew J , Giri, Sharmila ... - - Am J Surg Pathol - 2020 Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203 Straus, D. J. , Lacasce, A. S. , Juweid, M. E. , Kostakoglu, L. ... - - Blood - 2007 Abstract - Primary - Primary - Lymphoma - CALGB-50203
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011 Manuscript - Primary - Primary - Lymphoma - CALGB-50203
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018 Manuscript - Primary - Primary - Lymphoma - CALGB-50604
Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604) Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015 Abstract - Primary - Preliminary - Lymphoma - CALGB-50604
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)☆ Tallarico, Michael , Foster, Jared C. , Seisler, Drew ... - - J Geriatr Oncol - 2018 Manuscript - Secondary - Primary - Older Adult - A151611
Toxicities and related outcomes of elderly patients (≥65 years) with hematologic malignancies in the contemporary era (Alliance A151611) Tallarico, Michael , Foster, Jared , Seisler, Drew ... - ASH - Blood - 2016 Abstract - Primary - Primary - Older Adult - A151611 , CALGB-10101 , CALGB-10404 , CALGB-10501 , CALGB-19805 , CALGB-19901 , CALGB-50002 , CALGB-50103 , CALGB-50201 , CALGB-50401 , CALGB-50402 , CALGB-50501 , CALGB-50602 , CALGB-50701 , CALGB-50803
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma Ujjani, C. , Cheson, B. D. ... - ICML - Hematol Oncol - 2013 Abstract - Primary - Preliminary - Lymphoma - A051103
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 Ujjani, Chaitra S. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2016 Manuscript - Primary - Primary - Lymphoma - A051103
Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103) Ujjani, Chaitra , Jung, Sin-Ho , Pitcher, Brandelyn , Martin, Peter ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - A051103
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype Wilson, W. H. , Jung, S. H. , Porcu, P. , Hurd, D. , Johnson, J. ... - - Haematologica - 2012 Manuscript - Primary - Primary - Lymphoma - CALGB-50103
Multi-center study of dose-adjusted epoch-r in untreated diffuse large b-cell lymphoma: CALGB 50103 Wilson, W. H. , Zelenetz, A. D. , Niedzwiecki, D. , Hurd, D. D. ... - - Ann. Oncol. - 2008 Abstract - Primary - Primary - Lymphoma - CALGB-50103
Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303 Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016 Abstract - Primary - Primary - Lymphoma - CALGB-50303
